Monocolonal antibodies and antigen for human non-small cell lung carcinomas
US4906562A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 18, 1985 |
| Grant date | Mar 6, 1990 |
| Priority date | — |
| Expiry date | Oct 18, 2005 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. Also disclosed in a novel glycolipid antigen. The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the terminal carbohydrate sequence: GalNAc.beta.l.fwdarw.4Gal.beta.l.fwdarw.3GalNAc.beta.l.fwdarw.4Gal.beta.l. fwdarw.R.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.